For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > Investor Relations

Investor Relations

Overview

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Events & Presentations

Upcoming

Monday April 6, 2020 at 8:00 AM EDT
Ruxolitinib Cream: Phase 3 Data in Atopic Dermatitis

View All Events

Prior

Monday March 2, 2020 at 11:20 AM EST
Cowen and Company’s 40th Annual Health Care Conference

Thursday February 13, 2020 at 8:00 AM EST
Q4 2019 Incyte Corporation Earnings Conference Call

Monday January 13, 2020 at 9:00 AM PST
J. P. Morgan 38th Annual Healthcare Conference Q/A Session

View All Events

Press Releases

April 2, 2020

Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm


March 26, 2020

Incyte Names New Member to Its Board of Directors


March 24, 2020

Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference


View All Releases

Investor Contacts

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Copyright West LLC. Minimum 15 minutes delayed.

Annual Reports

Quarterly Reports

RSS Feeds


All Press Releases

All Events

All SEC Filings